SYNTHES®

K012589

FEB 0 7 2002

3.0 510(k) Summary

SPONSOR:	Synthes (USA) 1690 Russell Road Paoli, PA 19301 (610) 647-9700 Contact: Thomas M. Maguire
DEVICE NAME:	Fast Set Putty
CLASSIFICATION:	Class II, 21 CFR 882.5300: Methyl Methacrylate for Cranioplasty.
PREDICATE DEVICE:	Documentation was provided which demonstrated Fast Set Putty to be substantially equivalent to other previously cleared devices.
DEVICE DESCRIPTION:	Fast Set Putty is a putty-like calcium phosphate bone cement characterized by a rapid *in situ* setting time. The Fast Set Putty components are supplied sterile in two separate containers. The putty is intraoperatively prepared by manually mixing the components within a cup using a spatula. Once complete, the putty can be shaped and contoured by hand.
INTENDED USE:	Fast Set Putty is indicated for repairing or filling craniofacial defects and craniotomy cuts with a surface area no larger than $25cm^2$. Fast Set Putty is also indicated for the restoration or augmentation of bony contours of the craniofacial skeleton, including the fronto-orbital, malar and mental areas.
MATERIAL:	Calcium Phosphate

1/1

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

FEB 0 7 2002

Mr. Thomas M. Maguire
Project Leader, Regulatory Affairs
Synthes (USA)
1690 Russell Road
Paoli, Pennsylvania 19301

Re: K012589
Trade/Device Name: CRS Fast Set Putty
Regulation Number: 21 CFR 882.5300
Regulation Name: methyl methacrylate for cranioplasty
Regulatory Class: Class II
Product Code: GXP
Dated: December 6, 2001
Received: December 10, 2001

Dear Mr. Maguire:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

for Mark N. Melkerson

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

SYNTHES®

2.0 Indications for Use Statement

510(k) Number (if known): K012589

Device Name: Synthes (USA) Fast Set Putty

Indications/Contraindications:

Fast Set Putty is indicated for repairing or filling craniofacial defects and craniotomy cuts with a surface area no larger than $25cm^2$. Fast Set Putty is also indicated for the restoration or augmentation of bony contours of the craniofacial skeleton, including the fronto-orbital, malar and mental areas.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use_
(Per 21 CFR 801.109)

for Mark N. Melkerson
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K012589